Second chance at breast preservation: new study tests repeat radiation
NCT ID NCT06704659
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study explores whether women with recurrent breast cancer can safely have breast-conserving surgery and a second round of radiation instead of full mastectomy. It will enroll 60 patients who had prior radiation at least 3 years ago and have small, localized tumors. The goal is to see if this approach is safe and maintains quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- radiation therapy
- What this could lead to
- If successful, this could offer a breast-sparing treatment option for women with recurrent breast cancer, avoiding full mastectomy.
- What could go wrong
- This is a small, early-phase study with only 60 participants, and repeat radiation carries risks of tissue damage and complications. It may not be safe or effective for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2024
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
55 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The patient has a diagnosed breast cancer or tumor area in the breast with a maximum diameter of 3 cm, where a previous breast-conserving surgery has been performed (either invasive breast cancer or carcinoma in situ, DCIS). The patient has only a local recurrence, and imaging studies show no suspicion of metastases outside the breast (preoperative staging N0M0). At least 3 years have passed since the completion of prior radiation therapy. The new breast cancer can be technically treated with another breast-conserving surgery using a technique that does not require tissue transfer from areas opposite the removed tumor to restore the shape of the breast. The patient is at least 55 years old at the time of surgery. The patient is willing to participate in the study. The patient is capable of providing informed consent. Exclusion Criteria: * A booster dose, also known as a "boost," was administered during prior radiation therapy. Preoperative assessments suggest multifocal breast cancer, with the tumor area to be removed exceeding 3 cm. The planned radiation therapy per the study protocol cannot be administered due to factors such as shoulder joint stiffness, a pacemaker located in the radiation field, or a skin condition (e.g., scleroderma). The patient is unable to provide informed consent or is unwilling to participate in the study. Metastases outside the breast (e.g., axillary or distant metastases) are present.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Recurrent breast carcinoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Helsinki University Hospital
RECRUITINGHelsinki, Finland
-
Turku University Hospital
RECRUITINGTurku, Finland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor-Blood-Vessel blocker boost hormone therapy for advanced breast cancer?
- Could a gentler chemo work for older breast cancer patients?
- Major trial pits three chemo drugs against each other for advanced breast cancer
- Genetic clues in blood and tumors could personalize breast cancer care
- Immunotherapy-Chemo cocktail shows promise in tough breast cancer
- Could an extra antibody slow HER2+ breast cancer spread?